Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesSodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis
Nephrology Dialysis Transplantation, 08/26/09
Hoste EAJ et al. – The incidence of CI–AKI was higher than recently reported, and varied among study cohorts. We found a preventive effect of the use of sodium bicarbonate on the risk for CI–AKI, however, with borderline statistical significance. There was no effect on need for RRT or mortality. The relative low quality of the individual studies, heterogeneity and possible publication bias means that only a limited recommendation can be made in favour of the use of sodium bicarbonate.
Today in Chronic Dz/Renal Failure...keeping you current
Receive free subspecialty "5-minute updates" via email
Nephrogenic systemic fibrosis
Current Opinion in Rheumatology, 11/04/09
Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery
Critical Care, 11/06/09
Impact of Chronic Aspirin and Statin Therapy on Presentation of Patients With Acute Myocardial Infarction and Impaired Renal Function
Preventive Cardiology, 11/12/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Article Search
Sponsor